Latest news from Ferring Pharmaceuticals on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/retrospective-analysis-of-data-evaluating-safety-and-efficacy-of-rebyota-fecal-microbiota-live-jslm-in-a-real-world-patient-population-with-comorbidities-and-risk-factors-published-in-open-forum-infectious-diseases/?sc=rsin /articles/retrospective-analysis-of-data-evaluating-safety-and-efficacy-of-rebyota-fecal-microbiota-live-jslm-in-a-real-world-patient-population-with-comorbidities-and-risk-factors-published-in-open-forum-infectious-diseases/?sc=rsin Thu, 04 May 2023 09:30:16 EST REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection. Ferring Pharmaceuticals